Clinical and economic implications of urinary tract infections

Expert Review of Pharmacoeconomics and Outcomes Research

Volumn 17, Issue 4, 2017, Pages 377-383

  Steiger, Samantha N ^a   Comito, Rachel R ^a   Nicolau, David P ^a  

^a HARTFORD HOSPITAL   (United States)

Author keywords

antimicrobial resistance; clinical pathways; extended spectrum lactamases; Urinary tract infection

Indexed keywords

AMIKACIN; AMINOGLYCOSIDE ANTIBIOTIC AGENT; AMOXICILLIN; AMOXICILLIN PLUS CLAVULANIC ACID; AVIBACTAM PLUS CEFTAZIDIME; BETA LACTAM ANTIBIOTIC; CEFALEXIN; CEFEPIME; CEFTOLOZANE PLUS TAZOBACTAM; CEFTRIAXONE; CIPROFLOXACIN; COLISTIN; COTRIMOXAZOLE; ERTAPENEM; FOSFOMYCIN; IMIPENEM; LEVOFLOXACIN; NITROFURANTOIN; POLYMYXIN B; QUINOLINE DERIVED ANTIINFECTIVE AGENT; SULTAMICILLIN; VANCOMYCIN; ANTIINFECTIVE AGENT;

ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; ANTIBIOTIC THERAPY; CLINICAL PATHWAY; COMORBIDITY; COST CONTROL; CYSTITIS; DRUG EFFICACY; DRUG SAFETY; ENTEROCOCCUS; ESCHERICHIA COLI; HEALTH CARE COST; HEALTH CARE QUALITY; HUMAN; KLEBSIELLA; NONHUMAN; OUTPATIENT CARE; PATHOGENESIS; PRACTICE GUIDELINE; PREVALENCE; PROTEUS; PSEUDOMONAS AERUGINOSA; PYELONEPHRITIS; REVIEW; SINGLE DRUG DOSE; STAPHYLOCOCCUS SAPROPHYTICUS; TREATMENT OUTCOME; URINALYSIS; URINARY TRACT INFECTION; BACTERIUM; COST OF ILLNESS; DRUG EFFECTS; ECONOMICS; HOSPITALIZATION; ISOLATION AND PURIFICATION; MICROBIOLOGY; MULTIDRUG RESISTANCE; URINARY TRACT INFECTIONS;

ANTI-BACTERIAL AGENTS; BACTERIA; COST OF ILLNESS; DRUG RESISTANCE, MULTIPLE, BACTERIAL; HEALTH CARE COSTS; HOSPITALIZATION; HUMANS; URINARY TRACT INFECTIONS;

EID: 85027380418     PISSN: 14737167     EISSN: 17448379     Source Type: Journal    
DOI: 10.1080/14737167.2017.1358618     Document Type: Review

References (25)

1. Cardwell SM, Crandon JL, Nicolau DP, et al. Epidemiology and economics of adult patients hospitalized with urinary tract infections. Hosp Pract. 2016;44(1):33–40.•• A retrospective study concluding that risk-based empiric therapy and de-escalation may improve care and reduce costs associated with UTIs.
2. MacVane SH, Tuttle LO, Nicolau DP., Demography and burden of care associated with patients readmitted for urinary tract infection. J Microbiol Immunol Infect. 2015;48:517–524.•• A retrospective cohort study emphasizing the proper diagnosis and treatment of UTIs.
3. Hooton TM., Clinical practice. Uncomplicated urinary tract infection. N Engl J Med. 2012;366(11):1028–1037.
4. Hooton TM, Bradley SF, Cardenas DD, et al. Diagnosis, prevention, and treatment of catheter-associated urinary tract infection in adults:2009 international clinical practice guidelines from the Infectious Diseases Society of America. Clin Infect Dis. 2010;50(5):625–663.
5. Finer G, Landau D. Pathogenesis of urinary tract infections with normal female anatomy. Lancet Infect Dis. 2004;4(10):631–635.
6. National Institute of Diabetes and Digestive and Kidney Diseases. Bladder infection (urinary tract infection - UTI) in adults. 2016. Available from: https://www.niddk.nih.gov/health-information/urologic-diseases/bladder-infection-uti-in-adults
7. Gould CV, Umscheid CA, Agarwal RK, Kuntz G, Pegues DA and the Healthcare Infection Control Practices Advisory Committee (HICPAC). Guideline for prevention of catheterassociated urinary tract infections 2009. 2017 Feb:1-61. Available from:https://www.cdc.gov/infectioncontrol/guidelines/cauti/
8. MacVane SH, Tuttle LO, Nicolau DP. Impact of extended-spectrum β-lactamase-producing organisms on clinical and economic outcomes in patients with urinary tract infection. J Hosp Med. 2014;9:232–238.•• A retrospective, matched-cohort analysis concluding that UTIs caused by ESBLs are associated with significant clinical and economic burden.
9. Bouchillon SK, Badal RE, Hoban DJ, et al. Antimicrobial susceptibility of inpatient urinary tract isolates of Gram-negative bacilli in the United States:results from the study for monitoring antimicrobial resistance trends (SMART) program:2009-2011. Clin Ther. 2013;35:872–877.
10. Morrissey I, Hackel M, Badal R, et al. A review of ten years of the study for monitoring antimicrobial resistance trends (SMART) from 2002 to 2011. Pharmaceuticals (Basel, Switzerland). 2013;6:1335–1346.•• Ongoing global surveillance study helping to determine uropathogen prevalence and antibiotic susceptibility.
11. Gupta K, Hooton TM, Naber KG, et al. International clinical practice guidelines for the treatment of acute uncomplicated cystitis and pyelonephritis in women:a 2010 update by the Infectious Diseases Society of America and the European Society for Microbiology and Infectious Diseases. Clin Infect Dis. 2011;52(5):103–120.• A guideline discussing the treatment of women with acute uncomplicated cystitis and pyelonephritis.
12. Briongos-Figuero LS, Gomez-Traveso T, Bachiller-Luque P, et al. Epidemiology, risk factors and comorbidity for urinary tract infections caused by extended-spectrum beta-lactamase (ESBL)-producing enterobacteria. Int J Clin Pract. 2012;66(9):891–896.• A retrospective study concluding how identifying risk factors for ESBL UTIs facilitate early detection and improved patient prognosis.
13. Lee DS, Lee CB, Lee SJ. Prevalence and risk factors for extended spectrum-beta-lactamase-producing uropathogens in urinary tract infection. Korean J Urol. 2010;51(7):492–497.
14. Zmarlicka MT, Cardwell SM, Crandon JL, et al. Evaluation of a disease state management guideline for urinary tract infection. Int J Antimicrob Agents. 2016;47:451–456.•• A retrospective study concluding that UTI disease state management guidelines can improve patient outcomes.
15. Gibson K, Toscano J. Urinary tract infection update. Am J Clin Med. 2012;9(2):82-86. Available from: http://www.aapsus.org/wp-content/uploads/uti82.pdf
16. Bazaz R, Chapman AL, Winstanley TG. Ertapenem administered as outpatient parenteral antibiotic therapy for urinary tract infections caused by extended-spectrum-beta- lactamase-producing gram-negative organisms. J Antimicrob Chemother. 2010;65:1510–1513.
17. Veve MP, Wagner JL, Kenney RM, et al. Comparison of fosfomycin to ertapenem for outpatient or step-down therapy of extended-spectrum β-lactamase urinary tract infections. Int J Antimicrob Agents. 2016;48:56–60.• A retrospective cohort study concluding that fosfomycin is non-inferior to ertapenem for treating outpatient ESBL UTIs.
18. AVYCAZ (ceftazidime and avibactam) [package insert]. Dublin:Allergan Pharmaceuticals; 2017.
19. ZERBAXA (ceftolozane/tazobactam) [package insert]. Kenilworth (NJ):Merck Pharmaceuticals; 2014.
20. Thaden JT, Pogue JM, Kaye KS, et al. Role of newer and re-emerging older agents in the treatment of infections caused by carbapenem-resistant Enterobacteriaceae. Virulence. 2017;8:403–416.• A review discussing traditional and innovative therapies for CRE.
21. De Maio Carrilho C, De Oliveira L, Gaudereto J, et al. A prospective study of treatment of carbapenem-resistant Enterobacteriaceae infections and risk factors associated with outcome. BMC Infect Dis. 2016 Nov 3;16(1):629. DOI:10.1186/s12879-016-1979-z.
22. Zilberberg MD, Nathanson BH, Sulham K, et al. Carbapenem resistance, inappropriate empiric treatment and outcomes among patients hospitalized with Enterobacteriaceae urinary tract infection, pneumonia and sepsis. BMC Infect Dis. 2017 Apr 17;17(1):279. doi:10.1186/s12879-017-2383-z.
23. Tice AD, Rehm SJ, Dalovisio JR, et al. Practice guidelines for outpatient parenteral antibiotic therapy. Clin Infect Dis. 2004;38:1651–1672.• Guideline discussing the administration of outpatient parenteral antimicrobial therapy (OPAT).
24. Laupland KB, Valiquette L. Outpatient parenteral antimicrobial therapy. Can J Infect Dis Med Microbiol. 2013;24:9–11.
25. Halilovic J, Christensen CL, Nguyen HH. Managing an outpatient parenteral antibiotic therapy team:challenges and solutions. Ther Clin Risk Manag. 2014;10:459–465.